Company intelligence / Profile preview

Ferryx

Bristol, England, United Kingdomferryx.com ↗

Ownership: Private
Employees: ~3
Development stage: Commercial

Overview

Ferryx has launched its first commercial product, Ferrocalm, containing the FX856 bacterial strain to address gut inflammation and IBS symptoms. Early user results are positive. A clinical trial in IBD patients with FX856 was being planned as of late 2022.

Therapeutic areas: GastroenterologyOther
Modalities: Live biotherapeutic products (probiotics)
Industry: Biotech

Drug pipeline

1 asset

Ferrocalm

Unknown

Beyond the preview

Go deeper on Ferryx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ferryx.

Explore the full profile